{
	"columns": [
		{
			"label": "SimilarStudyID",
			"field": "SimilarStudyID"
		},
		{
			"label": "Title",
			"field": "Title"
		},
		{
			"label": "StudyLink",
			"field": "StudyLink"
		}
    ],
	
	"rows":[
   {
      "SimilarStudyID":"NCT01166230",
      "Title":"An Open, Non-interventional, Retrospective, Comparative, Multicenter Follow-up Study in Patients Included in the Previously Completed Clinical Study PCB305/04, to Assess Longer-term Recurrence Rates in Patients After Hexvixu00ae (Cysviewu00ae)Fluorescence Cystoscopy/Transurethral Resection of the Bladder (TURB) or White Light Cystoscopy/TURB",
      "StudyLink":"https://clinicaltrials.gov/ct2/show/results/NCT01166230"
   },
   {
      "SimilarStudyID":"NCT02552121",
      "Title":"Dose-escalating and Cohort Expansion Safety Trial of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMaxu00ae-TF-ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor",
      "StudyLink":"https://clinicaltrials.gov/ct2/show/results/NCT02552121"
   },
   {
      "SimilarStudyID":"NCT00598806",
      "Title":"A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial of Single-Dose Intravesical Apaziquone (EOquinu00ae) as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer (Protocol SPI-612)",
      "StudyLink":"https://clinicaltrials.gov/ct2/show/results/NCT00598806"
   },
   {
      "SimilarStudyID":"NCT00461591",
      "Title":"A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial of Single Dose Intravesical Apaziquone (EOquinu00ae) as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer (Protocol SPI-611)",
      "StudyLink":"https://clinicaltrials.gov/ct2/show/results/NCT00461591"
   },
   {
      "SimilarStudyID":"NCT00045630",
      "Title":"A Sequential Approach to the Treatment of Muscle Invasive, Non-Metastatic Urothelial Carcinoma of the Bladder: A Phase II Trial of Neoadjuvant Gemcitabine, Paclitaxel and Carboplatin With Molecular Correlates",
      "StudyLink":"https://clinicaltrials.gov/ct2/show/results/NCT00045630"
   },
   {
      "SimilarStudyID":"NCT00808639",
      "Title":"A Phase II Trial of Neoadjuvant Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma",
      "StudyLink":"https://clinicaltrials.gov/ct2/show/results/NCT00808639"
   },
   {
      "SimilarStudyID":"NCT00734994",
      "Title":"Pilot Study of External Hyperthermia and Intravesical Mitomycin-C To Treat Recurrent Bladder Cancer After Resection and Standard Adjuvant Therapy",
      "StudyLink":"https://clinicaltrials.gov/ct2/show/results/NCT00734994"
   },
   {
      "SimilarStudyID":"NCT02178241",
      "Title":"Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder",
      "StudyLink":"https://clinicaltrials.gov/ct2/show/results/NCT02178241"
   },
   {
      "SimilarStudyID":"NCT00506155",
      "Title":"A Phase II Clinical Trial of Neoadjuvant Chemotherapy With M-VAC Plus Avastin in Patients With Locally Advanced Urothelial Cancer",
      "StudyLink":"https://clinicaltrials.gov/ct2/show/results/NCT00506155"
   },
   {
      "SimilarStudyID":"NCT01589094",
      "Title":"Phase II Study of Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer",
      "StudyLink":"https://clinicaltrials.gov/ct2/show/results/NCT01589094"
   },
   {
      "SimilarStudyID":"NCT04125693",
      "Title":"A Roll-over Study to Provide Continued Treatment With Rogaratinib in Participants Who Were Enrolled in Rogaratinib Studies",
      "StudyLink":"https://clinicaltrials.gov/ct2/show/results/NCT04125693"
   }
]
}